Q5123 Rituximab-arrx - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Rituximab-arrx

Brand Name:

Riabni

Strength:

10mg

HCPCS:

Q5123

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

CD20

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

July 23, 2021

CMS Discontinuation Date:

Status:

In Use